Standard BioTools Inc.: diluted earnings per share

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Standard BioTools' selected 2019 and 2020 figures come from the historical Fluidigm Corporation filing. It excludes restricted stock units, performance share units and options because their effect is anti-dilutive during losses. The statement displays share counts in thousands with inline scale 3. Full selected counts and reported USD EPS remain on that historical filing basis. Read the source filing.

For 2023–2025, Standard BioTools reports total loss per share attributable to common stockholders, distinct from continuing-operations and discontinued-operations per-share figures. Its 2024 common-stockholder numerator includes an induced-conversion adjustment for Series B preferred stock. Potentially dilutive instruments are excluded as anti-dilutive. Weighted-average shares are in thousands and tagged with scale three; per-share figures are not scaled. The reported total and its components are retained without substituting consolidated net loss or recalculating rounded EPS. Read the source filing.

Selected filing history

Related financial histories

• Standard BioTools Inc.: total assets
• Standard BioTools Inc.: total liabilities
• Standard BioTools Inc.: stockholders equity
• Standard BioTools Inc.: cash and cash equivalents
• Standard BioTools Inc.: net income or loss
• Standard BioTools Inc.: operating cash flow
• Standard BioTools Inc.: capital expenditure payments
• Standard BioTools Inc.: revenue
• Standard BioTools Inc.: contract revenue excluding tax
• Standard BioTools Inc.: financing cash flow
• Standard BioTools Inc.: investing cash flow
• Standard BioTools Inc.: retained earnings or deficit
• Standard BioTools Inc.: basic weighted-average shares
• Standard BioTools Inc.: diluted weighted-average shares
• Standard BioTools Inc.: basic earnings per share
• Standard BioTools Inc.: income tax expense or benefit
• Standard BioTools Inc.: net property, plant and equipment
• Standard BioTools Inc.: share-based compensation expense
• Standard BioTools Inc.: operating income or loss
• Standard BioTools Inc.: current assets
• Standard BioTools Inc.: interest expense
• Standard BioTools Inc.: current liabilities
• Standard BioTools Inc.: current accounts payable
• Standard BioTools Inc.: goodwill carrying amount
• Standard BioTools Inc.: net finite-lived intangible assets
• Standard BioTools Inc.: net current accounts receivable
• Standard BioTools Inc.: common-stock repurchase payments
• Standard BioTools Inc.: operating expenses
• Standard BioTools Inc.: net inventory
• Standard BioTools Inc.: gross profit
• Standard BioTools Inc.: cost of revenue
• Standard BioTools Inc.: selling, general and administrative expense
• Standard BioTools Inc.: research and development expense

Inspect the source

Entity

Standard BioTools Inc. / CIK 0001162194

Captured

2026-09-20T07:43:18.588Z

SEC response SHA-256

a456503a84818adf93963f66898da8214b4c8773c8d6098feaf8922448cbaa0f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001162194.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))